Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics Limited has issued 30,969,360 ordinary fully paid shares without a disclosure under Part 6D.2 of the Corporations Act. The company confirms compliance with relevant provisions of the Corporations Act and states there is no excluded information that needs disclosure, potentially impacting its transparency and stakeholder trust.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development of radiopharmaceutical products. The company is primarily engaged in creating diagnostic and therapeutic solutions using radioactive substances, aiming to enhance the detection and treatment of various diseases.
Average Trading Volume: 4,325,527
Technical Sentiment Signal: Sell
Current Market Cap: A$56.02M
For an in-depth examination of RAD stock, go to TipRanks’ Stock Analysis page.